Interplay between the second messengers cAMP and Ca2+ is a hallmark of dynamic cellular processes. A common motif is the opposition of the Ca2+-sensitive phosphatase calcineurin and the major cAMP receptor, protein kinase A (PKA). Calcineurin dephosphorylates sites primed by PKA to bring about changes including synaptic long-term depression (LTD). AKAP79 supports signaling of this type by anchoring PKA and calcineurin in tandem. In this study, we discovered that AKAP79 increases the rate of calcineurin dephosphorylation of type II PKA regulatory subunits by an order of magnitude. Fluorescent PKA activity reporter assays, supported by kinetic modeling, show how AKAP79-enhanced calcineurin activity enables suppression of PKA without altering cAMP levels by increasing PKA catalytic subunit capture rate. Experiments with hippocampal neurons indicate that this mechanism contributes toward LTD. This non-canonical mode of PKA regulation may underlie many other cellular processes.
High-throughput affinity proteomics (AP) technologies, such as Olink and SomaScan, are central to biomarker discovery and clinical studies, but unlike mass spectrometry (MS)-based proteomics, they have lacked a dedicated, standards-driven open-data repository. To address this gap, we introduce the PRIDE Affinity Proteomics Archive (PRIDE-AP), a centralized, open, technology-agnostic repository extending the PRIDE infrastructure to support submission, storage, and reuse of AP datasets in compliance with FAIR principles. Each dataset receives a stable PAD identifier and DOI and undergoes automated validation. We extended the HUPO-PSI SDRF-Proteomics format and the PRIDE controlled vocabulary for AP experiments, and integrated quality-control statistics via the open-source library pyprideap. As of May 2026, PRIDE-AP includes 20 public datasets spanning 14 human diseases, with evidence for over 10,000 proteins. By enabling AP and MS datasets to be jointly deposited and linked, with protein-centric exploration cross-referenced to UniProt, PRIDE-AP enables cross-technology proteome interrogation at scale.